Diabetologie und Stoffwechsel 2025; 20(S 01): S39-S40
DOI: 10.1055/s-0045-1807431
Abstracts | DDG 2025
Poster
Posterwalk 4: Klinische Diabetologie Typ-1 & Typ-2 Diabetes

Impact of Age on the Efficacy and Safety of Once-Weekly Insulin Icodec vs. Once-Daily Insulin in Type 2 Diabetes (ONWARDS 1–5)

K Milek
1   Diabetologische Schwerpunktpraxis, Diabetologische Schwerpunktpraxis, Hohenmölsen – Weißenfels, Germany
,
AG D. Vianna
2   Hospital Nossa Senhora das Graças, Curitiba Diabetes Center, Department of Endocrine Diseases, Curitiba, Brazil
,
C Desouza
3   University of Nebraska Medical Center, University of Nebraska Medical Center, Omaha, Nebraska, United States
,
C Laugesen
4   Novo Nordisk A/S, Medical & Science, Søborg, Denmark
,
M Fragão Marques
5   Faculdade de Medicina da Universidade do Porto, Departamento de Cirurgia e Fisiologia, Porto, Portugal
,
P H Nielsen
6   Novo Nordisk A/S, Biostatistics RD, Søborg, Denmark
,
S S Shaikh
7   Prince Aly Khan Hospital, Department of Endocrinology, Mumbai, India
,
I Lingvay
8   Department of Internal Medicine and Peter O’Donnell School of Public Health, Endocrinology Division, Dallas, United States
› Author Affiliations
› Further Information
Also available ateRef
 
 

    Introduction & Objective: This post hoc analysis assessed the treatment effects of once-weekly insulin icodec (icodec) vs once-daily (OD) basal insulin comparators across different age groups in adults with T2D.

    Methods: Efficacy outcomes and hypoglycemia rates for icodec vs OD comparators across three age subgroups (<55, 55-64 and≥65 years) were assessed, by trial, in insulin-naïve (ONWARDS 1, 3, 5) and insulin-treated (ONWARDS 2, 4) adults with T2D.

    Results: There were no statistically significant treatment by subgroup interactions for change in A1C from baseline to planned end of treatment (EOT). A larger reduction in A1C with icodec was seen across age subgroups in ONWARDS 1-5, except for individuals≥65 years in ONWARDS 4, where the opposite trend was seen. Overall, rates of clinically significant and severe hypoglycemic episodes were low in both treatment arms across age subgroups. In ONWARDS 1-5, the proportions of individuals achieving A1C<7% without clinically significant or severe hypoglycemic episodes at planned EOT were higher for icodec vs OD comparators irrespective of age, except for individuals<55 and≥65 years in ONWARDS 4; no statistically significant difference was seen in the treatment by subgroup interaction across different age subgroups.

    Conclusion: Overall, efficacy and hypoglycemia outcomes were consistent for icodec vs OD comparators irrespective of age.


     

    Interessenkonflikt

    KM has participated in advisory boards and consultant groups and has acted as a speaker for Abbott Deutschland, AstraZeneca, Lilly Deutschland, MSD, Novo Nordisk, Sanofi-Aventis Deutschland GmbH at various symposia and congresses. KM has received grants in support of investigator and internal trials from Lilly Deutschland and MSD. • Anstellungsverhältnis oder Führungsposition • Besitz von Geschäftsanteilen, Aktien oder Fonds • Patente, Urheberrecht, Verkaufslizenz • Andere finanzielle Beziehungen • Immaterielle Interessenkonflikt bestehen nicht.

    Publication History

    Article published online:
    28 May 2025

    © 2025. Thieme. All rights reserved.

    Georg Thieme Verlag KG
    Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany